The immunochemistry results showed that high XIAP expression levels inversely correlated with carboplatin response (P=0.03) and progression-free survival (P=0.0068) in patients with ovarian cancer….XIAP may be a novel target for the treatment of carboplatin-resistant ovarian cancer.